Letrozole Tablet
Product Images NDC 50090-8002

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Letrozole (NDC 50090-8002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500908002)

LETROZOLE, USP 2.5 mg oral tablets by A-S Medication Solutions. Label shows NDC 50090-8002-0 with a lot number and storage instruction to keep at 77 degrees Fahrenheit. The package contains 90 film-coated tablets.*

FDA Label Image

Chemical Structure (Letrozole 01)

Chemical structure of letrozole, showing its molecular skeleton including a triazole ring and two cyanophenyl groups attached to a central carbon atom.*

FDA Label Image

Figure 1 (Letrozole 02)

A survival curve chart comparing two treatments, Letrozole and Tamoxifen, over a 72-month period. The graph includes patient risk numbers at various months and event counts, showing solid and dashed lines representing Letrozole and Tamoxifen, respectively. The y-axis ranges from 0.0 to 1.0, and the x-axis is labeled in months from 0 to 72.*

FDA Label Image

Figure 2 (Letrozole 03)

A Kaplan-Meier progression-free survival curve comparing Letrozole tablets 2.5 mg and tamoxifen 20 mg over 60 months. The y-axis represents the proportion progression-free, and the x-axis shows time in months. Letrozole shows a slightly higher progression-free rate throughout the period compared to tamoxifen.*

FDA Label Image

Figure 3 (Letrozole 04)

A survival curve chart comparing two treatments: letrozole 1st and tamoxifen 1st. The x-axis shows time in months (0 to 60), and the y-axis shows the proportion alive (0.0 to 1.0). Two lines, one solid for letrozole and one dashed for tamoxifen, show survival probabilities over time.*

FDA Label Image

Figure 4 (Letrozole 05)

A Kaplan-Meier survival curve chart showing time to progression in days for three treatment groups: Letrozole Tablets 0.5 mg, Letrozole Tablets 2.5 mg, and MA. The x-axis represents time to progression in days (0 to 1000), and the y-axis shows the proportion of patients without progression (0.0 to 1.0). Each treatment group is represented by a different line style.*

FDA Label Image

Figure 5 (Letrozole 06)

A line graph plotting time to progression (in days) with three survival curves representing treatment groups: Letrozole Tablets 0.5 mg, Letrozole Tablets 2.5 mg, and AG. The graph shows patient progression over approximately 1000 days, comparing the efficacy of different dosages and treatment conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.